JWJonathan P. Williams

Jonathan P. Williams

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jonathan P. Williams has a total of 47 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Frequent cannabis use and the association with seizure burden in drug‐resistant epilepsy

    by Santiago Philibert‐Rosas, Kaitlin A. Guston, Mariel Kalkach‐Aparicio, Abigail Keller, Sanaa Semia, Theodore Imhoff‐Smith, Cameron J. Brace, Steven E. Haworth, Felipe Branco de Paiva, Dace Almane, et al.

    Objective: Cannabis use has increased substantially, with modern products characterized by high tetrahydrocannabinol concentrations and variable composition. The relationship between frequent cannabis use and epilepsy outcomes remains uncertain. We examined the association between frequent cannabis use and epilepsy severity, clinical phenotype, and imaging characteristics in patients admitted to an epilepsy monitoring unit (EMU). Methods: This retrospective cohort study included adults with drug‐resistant epilepsy admitted to a tertiary care EMU. Patients were classified based on cannabis use documented in the electronic medical record over the year prior to admission. Frequent use was defined as cannabis use on ≥20 days/month; patients with low use were excluded. Primary outcomes included markers of epilepsy severity, including time from epilepsy onset to EMU admission, presence and frequency of focal to bilateral tonic–clonic seizures (FBTCS), and antiseizure medication (ASM) burden. Secondary analyses evaluated epilepsy syndrome and mesial temporal lobe volumetric measures. Results: Sixty‐four patients were included (42 nonusers and 22 frequent users). Frequent cannabis use was associated with shorter time from epilepsy onset to EMU admission (mean [SD] = 5.0 [4.2] vs. 18.1 [16.3] years, p = .004), higher prevalence of FBTCS (90.9% vs. 57.1%, p = .04), greater annualized FBTCS frequency (mean [SD] = 3.00 [3.63] vs. 1.32 [3.87], p = .003), and higher ASM burden (mean [SD] = 3.05 [1.00] vs. 2.21 [1.14], p = .027). All frequent cannabis users had temporal lobe epilepsy (TLE), although the between‐group difference in TLE prevalence was not statistically significant. No significant group differences were observed in imaging analysis. Significance: In this cohort of patients with drug‐resistant epilepsy, frequent cannabis use was associated with markers of increased epilepsy severity, including higher FBTCS burden, shorter time to specialized EMU evaluation, and greater ASM requirements. Prospective studies using objective cannabis exposure measures are needed to clarify the relationship between cannabis use and epilepsy outcomes.

  • Open Access

    Naturalistic driving behavior among older adults with and without epilepsy: A pilot study

    by Jonathan P. Williams, Yiqi Zhu, Ganesh M. Babulal


  • Association of Social Determinants of Health With Genetic Test Request and Completion Rates in Children With Neurologic Disorders

    by Jordan Janae Cole, Jonathan P. Williams, Angela D. Sellitto, Laura Rosa Baratta, Julia B. Huecker, Dustin Baldridge, Thomas Kannampallil, Christina A. Gurnett, Joyce E. Balls-Berry


  • Hakuna Matata

    by Jonathan P. Williams, Ganesh M. Babulal

  • The effect of anti-seizure medications on Alzheimer's disease (AD) risk and AD-related symptoms: A scoping review

    by Jonathan P Williams, Yiqi Zhu, Ramkrishna K Singh, Kebede Beyene, Rohan Rani, Xian Kapetanakos, Amanda Dias, Katherine McGuire, Ramana Kolady, Kim Lipsey, et al.

    Background: As the fastest-growing segment of the population, adults over 65 are at the most significant risk for Alzheimer's disease (AD). Older adults often use anti-seizure medications (ASMs), which can negatively impact cognitive function, mood, and behavior, mimicking AD or its symptoms. Understanding the effects of ASMs across diverse older adults is crucial, given that some ethnoracial groups are at higher risk for AD or more severe symptoms compared to non-Hispanic Whites. Objective: To summarize the current evidence on the association of ASMs with AD risk and AD-related symptoms and explore the inclusion of ethnoracial minority groups in these studies. Methods: Data sources included PubMed/MEDLINE, EMBASE, and SCOPUS for English-language studies published between 1990–2024. Selected studies were peer-reviewed, cross-sectional, longitudinal, case-control, and clinical trials on AD dementia or related symptoms and ASMs. Study quality was rated by the Oxford Centre for Evidence-Based Research Medicine. Results: A total of 27 studies with 1,241,796 participants were included. Data on AD risk from level IB-IIIB evidence studies showed mixed results, with some indicating an increased association with ASM use [OR = 1.05–1.16, 95% CI: 1.01–1.24]. Studies on AD-related symptoms from level IB-IV evidence also showed mixed results. Only three North American studies explicitly included race/ethnicity; most were conducted in European countries. Conclusions: ASM use may be modestly associated with an increased risk of AD among the older adult population, but current data are inconclusive. The association of ASMs on AD-related symptoms varied. Future studies should emphasize reporting sociodemographic data and include diverse cohorts to enhance the applicability of findings.


  • Trends in Racial and Ethnic Diversity in Vascular Neurology Fellowships From 2006 to 2018: A Cross-Sectional Analysis

    by Saurav Das, Nathan Farkas, Michael Binkley, Jonathan Williams, Ima M. Ebong, Ozan Akca, Andria Ford, Renee Van Stavern, Allyson Zazulia

    Background: Workforce diversity in vascular neurology is a crucial component of reducing disparities in stroke care and outcomes. The objective of this study is to describe trends in the racial and ethnic diversity of neurology residents pursuing vascular neurology fellowship and propose an actionable plan for improvement. Methods: This was a cross-sectional study of race/ethnicity of neurology residents and vascular neurology fellows using published Graduate Medical Education census reports from 2006, when race/ethnicity data were first included, to 2018. Percentage of trainees underrepresented in medicine are reported for 3-year epochs and were analyzed using the Cochran-Armitage test (χ 2 test for trend). Results: Across the study period, underrepresented in medicine representation has not changed significantly among all neurology residents and subspecialty fellows (11.9% in 2006–2009; 12.5% in 2015–2018, P =0.82) nor among neurology residents alone (12.0% in 2006–2009; 12.6% in 2015–2018, P =0.81). Among vascular neurology fellows, however, there was a significant downtrend of underrepresented in medicine representation from 16.9% in 2006 to 2009 to 9.3% in 2015 to 2018 ( P =0.013). Conclusions: Racial/ethnic underrepresentation among all neurology residents as well as those pursuing vascular neurology fellowship has persisted across the study period. Concerted efforts should be pursued to increase diversity in neurology residents and vascular neurology fellowship training.